Metabolic signature shift in type 2 diabetes mellitus revealed by mass spectrometry-based metabolomics
- PMID: 23633210
- DOI: 10.1210/jc.2012-4132
Metabolic signature shift in type 2 diabetes mellitus revealed by mass spectrometry-based metabolomics
Abstract
Objective: Metabolic profiling of small molecules offers a snapshot of physiological processes. To identify metabolic signatures associated with type 2 diabetes and impaired fasting glucose (IFG) beyond differences in glucose, we used mass spectrometry-based metabolic profiling.
Research design and methods: Individuals attending an institutional health screen were enrolled. IFG (n = 24) was defined as fasting glucose (FG) of 6.1 to 6.9 mmol/L and 2-hour post glucose load <11.1 mmol/L or glycosylated hemoglobin <6.5%, type 2 diabetes (n = 27), FG ≥7.0 mmol/L, or 2-hour post glucose load ≥11.1 mmol/L, or glycosylated hemoglobin ≥6.5%, and healthy controls (n = 60), FG <6.1 mmol/L. Fasting serum metabolomes were profiled and compared using gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry.
Results: Compared to healthy controls, those with IFG and type 2 diabetes had significantly raised fructose, α-hydroxybutyrate, alanine, proline, phenylalanine, glutamine, branched-chain amino acids (leucine, isoleucine, and valine), low carbon number lipids (myristic, palmitic, and stearic acid), and significantly reduced pyroglutamic acid, glycerophospohlipids, and sphingomyelins, even after adjusting for age, gender, and body mass index.
Conclusions: Using 2 highly sensitive metabolomic techniques, we report distinct serum profile change of a wide range of metabolites from healthy persons to type 2 diabetes mellitus. Apart from glucose, IFG and diabetes mellitus are characterized by abnormalities in amino acid, fatty acids, glycerophospholipids, and sphingomyelin metabolism. These early broad-spectrum metabolic changes emphasize the complex abnormalities present in a disease defined mainly by elevated blood glucose levels.
Similar articles
-
Integrated biomarker for type 2 diabetes mellitus and impaired fasting glucose based on metabolomics analysis using ultra-high performance liquid chromatography quadrupole-Orbitrap high-resolution accurate mass spectrometry.Rapid Commun Mass Spectrom. 2020 Jun 30;34(12):e8779. doi: 10.1002/rcm.8779. Rapid Commun Mass Spectrom. 2020. PMID: 32159245
-
The metabolites in peripheral blood mononuclear cells showed greater differences between patients with impaired fasting glucose or type 2 diabetes and healthy controls than those in plasma.Diab Vasc Dis Res. 2017 Mar;14(2):130-138. doi: 10.1177/1479164116678157. Epub 2016 Dec 21. Diab Vasc Dis Res. 2017. PMID: 28185532
-
Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.Rom J Intern Med. 2003;41(2):153-62. Rom J Intern Med. 2003. PMID: 15526500 Clinical Trial.
-
Metabolomics in human type 2 diabetes research.Front Med. 2013 Mar;7(1):4-13. doi: 10.1007/s11684-013-0248-4. Epub 2013 Feb 2. Front Med. 2013. PMID: 23377891 Review.
-
The role of metabolomics in personalized medicine for diabetes.Per Med. 2021 Sep;18(5):501-508. doi: 10.2217/pme-2021-0083. Epub 2021 Aug 18. Per Med. 2021. PMID: 34406076 Review.
Cited by
-
Characterizing poorly controlled type 2 diabetes using 1H-NMR metabolomics.Metabolomics. 2024 May 11;20(3):54. doi: 10.1007/s11306-024-02127-w. Metabolomics. 2024. PMID: 38734832 Free PMC article.
-
A two-sample Mendelian randomization study explores metabolic profiling of different glycemic traits.Commun Biol. 2024 Mar 8;7(1):293. doi: 10.1038/s42003-024-05977-1. Commun Biol. 2024. PMID: 38459184 Free PMC article.
-
Integrated 16S rRNA sequencing and metabolomic analysis reveals the potential protective mechanism of Germacrone on diabetic nephropathy in mice.Acta Biochim Biophys Sin (Shanghai). 2024 Mar 25;56(3):414-426. doi: 10.3724/abbs.2024021. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 38429975 Free PMC article.
-
Metabolite profiles of diabetes mellitus and response to intervention in anti-hyperglycemic drugs.Front Endocrinol (Lausanne). 2023 Oct 31;14:1237934. doi: 10.3389/fendo.2023.1237934. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38027178 Free PMC article. Review.
-
Lipidomics analysis of impaired glucose tolerance and type 2 diabetes mellitus in overweight or obese elderly adults.Endocr Connect. 2023 Nov 15;12(12):e230212. doi: 10.1530/EC-23-0212. Print 2023 Dec 1. Endocr Connect. 2023. PMID: 37878774 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical